ArticleCase reports in oncology
Long-Term Complete Response of Unresectable Small-Cell Neuroendocrine Carcinoma of the Gallbladder following Chemotherapy and Radiotherapy: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Small-cell neuroendocrine carcinoma of the gallbladder (SCNEC-GB) is an exceptionally rare and aggressive malignancy, representing fewer than 2% of gallbladder cancers. Most patients present with advanced, unresectable disease, and survival rarely exceeds 1 year despite therapy. Case Presentation: We describe a patient in whom SCNEC-GB was discovered incidentally during routine preoperative workup for hernia repair. Imaging revealed a bulky gallbladder mass with hepatic invasion and regional lymphadenopathy; pathology confirmed SCNEC with a Ki-67 of 100%. A multidisciplinary tumor board deemed the tumor unresectable, and systemic treatment was initiated. The patient received 6 cycles of platinum-etoposide chemotherapy, which achieved marked regression, followed by hypofractionated radiotherapy to the residual primary and nodal sites. Follow-up PET/CT demonstrated a complete radiological and metabolic response. The patient has now maintained long-term disease control for more than 18 months, with no evidence of recurrence or new metastases. Such durable remission in advanced SCNEC-GB is extraordinarily uncommon. Conclusions: This case highlights the potential of multimodal therapy to achieve long-term disease control in unresectable disease and underscores the need for collaborative efforts to define optimal strategies for this rare and lethal malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.